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a b s t r a c t
Predisposition to genital infections and urinary tract infections (UTIs) in type 2 diabetes
mellitus (T2DM) results from several factors such as glucosuria, adherence of bacteria to the
uroepithelium and immune dysfunction. The tendency to develop these infections could be
even higher in patients with T2DM treated with the emerging class of sodium–glucose
cotransporter-2 (SGLT2) inhibitors. Studies have shown that pharmacologically-induced
glucosuria with SGLT2 inhibitors raises the risk of developing genital infections and, to a
relatively lesser extent, UTIs. However, a definitive dose relationship of the incidence of
these infections with the SGLT2 doses is not evident in the existing data. Therefore, the
precise role of glucosuria as a causative factor for these infections is yet to be fully
elucidated.
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Type 2 diabetes mellitus (T2DM) is a debilitating disease with
multiple complications resulting from hyperglycaemia, inflam-
mation, and possibly immune dysfunction. Inaddition to macro-
and micro-vascular damage, T2DM is also associated with
increased risks of asymptomatic bacteriuria (ASB), urinary tract
infections (UTIs), and non-sexually transmitted genital infec-
tions (vulvovaginal infections and balanitis) [1,2]. ASB is defined
as two consecutive voided urine specimens with isolation of the
same bacterial strain in quantitative counts 105 colony-
forming units per millilitre collected from a patient without
symptoms of a UTI [3]. The presence of ASB (most commonly
caused by Escherichia coli [E. coli] and Klebsiella pneumoniae [K.
pneumoniae]) is a major risk factor for developing symptomatic
UTI [4]. Patients with diabetes generally present with symptoms
of UTIs similar to those reported in healthy controls. Complica-
tions of UTIs are also more common in patients with diabetes [5],
and this population has an increased risk of acute upper UTI
(pyelonephritis) requiring hospital admission [6]. Emphysema-
tous pyelonephritis, a severe manifestation of this disease, is
seen almost exclusively in patients with diabetes.
This review article aims to explore the relationship
between diabetes and UTIs and genital infections, particularly
in the context of emerging new therapies for T2DM that
pharmacologically increase urinary glucose concentrations.
2. Search strategy
We conducted a search of the scientific literature to identify
relevant studies in MEDLINE (1990–2012) using the search
terms–type 2 diabetes, infections, urinary, vaginitis, balanitis
and bacteriuria. We limited the literature searches to humans
and English-language publications. The searches were sup-
plemented by screening reference lists of included studies. Of
the articles searched using the above strategy, 52 references
were identified for inclusion in this review. Seven of these
references examined prevalence and/or pathogenesis of ASB.
Further, a total of 6 and 13 articles assessed incidence and/or
pathogenesis of genital infections and of UTIs, respectively.
The remaining references included data on events of genitalinfections and of UTIs reported in the SGLT-2 inhibitor class of
glucose-lowering drugs.
3. Prevalence of ASB and associated risk
factors in patients with T2DM
Various studies have estimated the prevalence of ASB or the
incidence of UTIs in patients with diabetes [1,4,7]. A large
majority of studies have shown a clear association between
prevalence of ASB and diabetes, particularly in women [8].
However, ASB has not been shown to be associated with
unfavourable long-term outcomes [9].
A systematic review and meta-analysis of data from 22
observational studies (16 cross-sectional and 5 follow-up
studies) published between 1966 and 2007 provided a large
volume of available data on the risk of ASB in patients with
diabetes. All of the data in the current review for the prevalence
of ASB come from the review of Renko et al. The results from this
meta-analysis showed that ASB was present in 12.2% of patients
with diabetes and 4.5% of patients in the healthy control group.
The prevalence of ASB was higher in both women (14.2% vs.
5.1%; odds ratio (OR): 2.6 [1.6–4.1]) and men (2.3% vs. 0.8%; OR: 3.7
[1.3–10.2]) with diabetes compared with healthy controls [10].
Four studies in this meta-analysis assessed the effect of
diabetes duration on the prevalence of ASB, and the results
indicated that the mean diabetes duration was only very slightly
longer in patients with ASB than in those without ASB (pooled
difference of 0.17 years [95% confidence interval (CI):0.03–0.31];
p = 0.01). Furthermore, the mean glycated haemoglobin (HbA1c)
levels were similar in patients with or without ASB (pooled
difference 0.2% [0.1, 0.5]; p = 0.14) suggesting that the
increased prevalence of ASB may not be a direct consequence
of poor glycaemic control of diabetes [10]. Supplementary Table
1 includes tabulated data for the risk of ASB in patients included
in this systematic review and meta-analysis.
4. Incidence of UTIs and associated risk
factors in patients with T2DM
A recent UK-based observational study in a primary care setting
quantified the incidence of UTIs among patients with diabetes
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diabetes [11]. A nearly 60% increase in the risk of UTIs was
observed among patients with T2DM (adjusted relative risk [RR]
[95% CI] = 1.53 [1.46–1.59]); when stratified by both gender and
age, the incidence of UTIs was highest in female patients with
diabetes (1-year incidence/1000 patient years [PY] [95%
CI] = 91.1 [84.3–99.4]) and lowest in male patients without
diabetes (1-year incidence/1000 PY [95% CI] = 45.7 [44.0–47.5]).
The study identified possible risk factors for UTIs as female
gender, pregnancy, older age, UTIs in previous six months,
prevalent diabetes, and poor glycaemic control (incidence [95%
CI] in ‘poorly controlled’ DM [HbA1c >8.0% {64 mmol/mol} or
switch to, or add-on of insulin] = 46.2/1000PY [43.8–48.7] vs.
39.4/1000PY [37.6–41.1] in ‘fairly controlled’ DM [no HbA1c
measure >8.0% {64 mmol/mol} during the study period]).
A study in 1157 Indian patients with T2DM [12] showed an
association between the percentage of patients with UTIs and
duration of diabetes (41.8% [10 years] vs. 58.2% [10 years] of
146 men with UTIs [p = 0.07], and 42.4% [10 years] vs. 57.6%
[10 years] of 349 women with UTIs [p = 0.007]), and poor
glycaemic control (19.3% [HbA1c <8.0% {64 mmol/mol}], 13.2%
[HbA1c range: 8.0–9.0% {64–75 mmol/mol}] and 64.9% [HbA1c
9.0% {75 mmol/mol}] in men [p < 0.0001], and 22%, 17.1% and
61.9%, respectively, in women [p < 0.0001]). The incidence of
UTIs was significantly higher in women compared with men
(47.9% vs. 34.1%, respectively, p < 0.0001). Perhaps due to
cultural differences, reported rates of genital infections and
UTIs may vary by geography. However, the risk factors are
consistent, with increased incidences of these infections
particularly seen in female patients with T2DM.
T2DM is also associated with more serious manifestations
of UTIs. In one study, diabetes was estimated to increase the
probability of acute pyelonephritis requiring hospital admis-
sion by 20–30 fold in patients under the age of 44 years and by
three- to five-fold in patients over the age of 44 years [6].
Studies have also reported an increased incidence of bilateral
kidney infection (identified by X-ray and CT scan) in patients
with diabetes [13]. Furthermore, bacteraemia is more likely to
occur from UTIs in patients with diabetes compared with the
group without diabetes [14].
5. Pathophysiology of ASB and UTIs in
patients with T2DM
There are several mechanisms that may explain the associa-
tion between T2DM and UTIs. These include altered growth
conditions (as a result of glucosuria and/or diabetes-asso-
ciated bladder dysfunction), and altered pathogen–host inter-
actions as a result of diabetes.
5.1. Glucosuria
One study reported that urine samples with glucose con-
centrations between 100 and 1000 mg/dL (i.e. equivalent
to moderate to severe glucosuria) enabled significantly
enhanced bacterial growth after 6 h, compared with normal
urine ( p < 0.01) [15]. Furthermore, a clinical study showed
an association between glucosuria and ASB, where urinary
glucose concentrations of 352.2  458.8 and 62.4  207.5 mg/dL( p < 0.05) were reported in patients with diabetes and ASB
and those without ASB, respectively [16]. However, this
pattern is not seen in all studies. For example, no association
between glucosuria and ASB was noted in a large cohort of 636
women with diabetes, where 42% of the women without and
38% of the women with ASB had glucosuria ( p = 0.4) [17]. It is
possible that there is a threshold urinary glucose concentra-
tion above which ASB occurs more frequently. However, there
are currently no in vivo data to quantify this. A study
conducted in 348 women with T2DM reported various risk
factors for the development of UTI in these women; the only
significant factor was the presence of ASB at baseline.
Glucosuria was not associated with the development of a
symptomatic UTI in this study [18].
5.2. Adherence of bacteria to the uroepithelium
Increased adherence of bacteria to uroepithelial cells has been
observed in patients with diabetes, particularly E. coli expres-
sing type-1 fimbriae. This may play a role in the pathogenesis
of UTIs and increased prevalence of bacteriuria in this
population [19]. Adherence of E. coli with type 1 fimbriae to
uroepithelial cells is higher in patients with poor glycaemic
control. It has been suggested that the altered adherence may
be due to a difference in the type 1 fimbriae receptors on
uroepithelial cells of patients with and without diabetes. In
particular, altered glycosylation of uroplakins, the major
glycoproteins of urothelial apical plaques that line the bladder
mucosa, has been observed in patients with diabetes [20].
5.3. Immune dysfunction
Hyperglycaemic environment has been observed to alter
immune function in patients with diabetes. Several aspects
of immunity including polymorphonuclear leukocyte function
and adhesion, chemotaxis and phagocytosis may be affected
[21]. This may contribute to the pathogenesis of urinary tract
infections in patients with diabetes. Lower urinary concentra-
tions of interleukin-8 and interleukin-6 ( p = 0.1 and p < 0.001,
respectively) in women with diabetes have been shown to
correlate with a lower urinary leukocyte cell count, which may
contribute to the increased incidence of UTIs in this patient
group [22,23].
6. Epidemiology of genital infections and
associated risk factors in patients with T2DM
Various studies have evaluated the prevalence of non-
sexually-transmitted genital infections in diabetes [24]. The
increased likelihood of genital infections in patients with
T2DM is familiar to physicians and their patients. However,
the exact nature of this condition deserves further discussion.
A UK-based population study in a primary care setting
evaluated the incidence of genital infections (vaginitis
[n = 125,237] and balanitis [n = 146,603]) among patients with
T2DM vs. patients without diabetes [25]. The results from this
large population-based study indicated that patients with
T2DM have an increased risk of developing genital infections
(RR [95% CI] = 1.81 [1.64–2.00] in the vaginitis cohort and 2.85
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groups (e.g. RR [95% CI] = 7.60 [3.57–16.20] in the balanitis age
18–39 years cohort), and in patients with poorly controlled
diabetes (e.g. in patients receiving glucose-lowering therapy,
in the first HbA1c quintile [mean HbA1c = 5.8 {40 mmol/mol}],
adjusted RR [95% CI] for vaginitis = 0.63 [0.38–1.06]; whereas in
the fifth HbA1c quintile [mean HbA1c = 9.7 {83 mmol/mol}],
adjusted RR for vaginitis = 1.76 [1.3–2.38]).
A study conducted in 166 Indian women [26] included 78
patients with diabetes and 88 age- and BMI-matched controls.
All subjects were assessed for symptoms and signs of
vulvovaginal candidiasis (VVC), and a clinical diagnosis was
established by fungal culture and direct microscopy. Candida
species were isolated in 36 (46%) and 21 (23%) patients with
and without diabetes, respectively ( p = 0.0025). The most
common species of candida isolated among patients with
diabetes and VVC were C. glabrata (39%), C. albicans (25%) and C.
tropicalis (17%). In contrast, C. albicans, C. glabrata and C.
hemulonii comprised 30% each in the control group with none
reporting C. tropicalis infection in this group. The mean HbA1c
in patients with diabetes and VVC was significantly higher in
comparison with those without infection (12.8% {116 mmol/
mol} vs. 9.7% {83 mmol/mol}, respectively, p = 0.001), which
supports a link between hyperglycaemic environment and an
increased risk of VVC.
7. Pathophysiology of genital infections in
patients with T2DM
It is well established that yeasts thrive in a sugar-rich
environment, and therefore, it is logical to hypothesize that
high glucose concentrations in patients with diabetes may be
responsible for promoting the occurrence and recurrence of
candidiasis. There are several potential mechanisms by which
hyperglycaemia may facilitate vaginal candidal colonization.
Hyperglycaemia impairs various aspects of host defense,
including neutrophils and complement proteins, and also
promotes the virulence of infecting organisms in patients with
diabetes. One study examined neutrophil killing of C. albicans in
the presence of increased concentrations of glucose [27].
Lucigenin-enhanced chemiluminescence showed that
increases in glucose concentration led to increased aldose
reductase activity, which was accompanied by sorbitol accu-
mulation in neutrophils. As oxidative killing and sorbitol
production are both NADPH-dependent, it was possible that
competition for this electron donor is responsible for the
inhibited neutrophil-mediated killing in patients with diabetes.
Studies have indicated that several organisms responsible
for genital infections in patients with diabetes may possess
unique mechanisms of virulence that flourish in the hypergly-
caemic environment. C. albicans produces a glucose-inducible
protein, which is structurally and functionally similar to a
complement receptor CD11b/CD18, a protein found on mam-
malian phagocytes [28]. This protein mediates yeast adhesion to
vaginal epithelium, and disrupts phagocytosis by the host. This
mechanism may help to explain the increased adhesiveness of
C. albicans to vaginal epithelial cells of women with diabetes
observed in an in vitro study conducted using cells collected
from a group of 347 women [29].8. The effect of pharmacologically-induced
glucosuria on genital and urinary tract infections
Sodium–glucose cotransporter-2 (SGLT2) inhibitors are a new
class of oral diabetes medication. These agents induce renal
glucosuria by selectively targeting the renal SGLT2 transporter
in patients with T2DM [30,31]. SGLT2 inhibitors in clinical
development include dapagliflozin, canagliflozin, ipragliflo-
zin, empagliflozin and tofogliflozin. Of these, dapagliflozin
currently provides the large majority of information on SGLT2
inhibitors in the public domain.
The pharmacologically-induced increased urinary glucose
concentration with this class of drugs might provide a
favourable growth environment for otherwise commensal
genital microorganisms, and could potentially increase the
risk for vulvovaginitis and balanitis. The possibility of UTIs has
also been raised as a concern with SGLT2 inhibitors. Data from
controlled clinical trials with SGLT2 inhibitors may provide an
opportunity to evaluate the association between elevated
urinary glucose, and the risk for either genital infections or/
and UTIs.
8.1. Dapagliflozin
Dapagliflozin dose-dependently induces glucosuria in patients
with T2DM. Glucosuria was observed throughout a 24-h dosing
interval with 5-, 25-, and 100-mg doses of dapagliflozin;
urinary glucose excretion on day 1 was 45.2, 75.3, and 81.3 g/day,
respectively, and after 2 weeks of once-daily treatment, it was
36.6, 70.1, and 69.9 g/day, respectively [30]. Long-term treatment
with dapagliflozin 10 mg as add-on to metformin showed that
increased urinary glucose excretion with dapagliflozin was
maintained for up to 102 weeks. The mean change from
baseline at week 102 in the urinary glucose-to-creatinine ratio
was 31.8 g/g for dapagliflozin 10 mg dose vs. 0.21 for placebo
[32].
Pooled data from 12 double-blind controlled clinical trials
of dapagliflozin provided an opportunity to evaluate the effect
of pharmacologically-induced glucosuria on the incidence of
UTIs [33]. ASB was not evaluated in these studies. Patients with
T2DM were treated with dapagliflozin (2.5–10 mg/day) for up to
24 weeks (3 studies–12 weeks; 9 studies–24 weeks). Dapagli-
flozin 10 mg was evaluated in all the studies that are
presented, while dapagliflozin 5 mg was evaluated in 11 of
the 12 studies. At 24 weeks, mean changes from baseline in
urine glucose were 241, +2150 and +2592 mg/dL in the
placebo, dapagliflozin 5 and 10 mg groups, respectively
(baseline values were 511, 511 and 450 mg/dL, respectively).
8.1.1. Confirmed UTIs in the pooled analysis of dapagliflozin
clinical trials
A rigorous effort was made to capture all signs, symptoms and
events suggestive of UTIs. Symptoms spontaneously reported
by study participants, as well as those reported following pro-
active questioning of patients at each visit, were recorded
throughout the dapagliflozin clinical program. The pro-active
questioning included dysuria, urgency or frequency of urina-
tion, suprapubic or perineal discomfort, flank, back, or
abdominal pain, costovertebral angle tenderness, nausea,
Table 1 – Diagnosis of UTIs in dapagliflozin trials (up to 24 weeks).
Placebo Dapagliflozin 5 mg Dapagliflozin 10 mg
Overall number of patients, N 1393 1145 1193
Patients with diagnosis of UTI, n (%) 52 (3.7) 65 (5.7) 51 (4.3)
Patients with history of recurrent UTI, n (%) 35 (2.5) 23 (2.0) 34 (2.8)
Patients with a prior history of recurrent UTI
with clinical diagnoses of UTI, n (%)
6/35 (17.1) 4/23 (21.1) 6/34 (17.6)
Women
N 677 581 598
Women with diagnosed UTI, n (%) 45/677 (6.6) 55/581 (9.5) 46/598 (7.7)
Men
N 716 564 595
Men with diagnosed UTI, n (%) 3/716 (0.4) 6/564 (1.1) 4/595 (0.7)
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possibility of patients not recognizing certain symptoms as
being relevant to the study. Investigators then performed urine
cultures to confirm diagnosis in suspected cases, and all adverse
events were reported. For safety signal detection, data were
analysed according to a wide range of pre-specified preferred
terms from the Medical Dictionary for Regulatory Activities
(MedDRA), which included signs, symptoms, and abnormal
laboratory findings suggestive of UTIs, as well as clinical
diagnoses. These preferred terms were described as ‘‘events
suggestive of UTIs’’ and a case-report questionnaire was
completed by the investigator if any such term was reported.
In a second analysis, 49 pre-specified, preferred terms that
related to confirmed clinical diagnoses of UTIs were assessed.
The rates of clinically diagnosed UTIs were slightly higher
in patients receiving dapagliflozin than receiving placebo.
Clinically diagnosed UTIs were more frequent in women than
men (Table 1) [33].
Prior history of recurrent UTIs was relatively uncommon
(2–3%), but was associated with an increased incidence of
episodes suggestive of UTIs irrespective of treatment group.
Because history of UTI is a strong risk factor for UTI, the UTI
incidence may be lower than expected in the dapagliflozin
clinical trial programme. Most first events of UTIs occurred
early in the course of treatment, and recurrent infection was
uncommon. Most of the organisms identified were well-
established causes of UTIs in the general population, e.g. E. coli,
Klebsiella sp, and Proteus sp.
Most UTIs responded to treatment with standard anti-
microbial medications (71% and 84% of episodes in the
dapagliflozin 5 and 10 mg groups, respectively, and 89% of
those in the placebo group). Pyelonephritis was infrequent in
both treatment groups (0% and 0.1% in the dapagliflozin 5 and
10 mg groups, respectively, and 0.1% in the placebo group).
Interruption or discontinuation of dapagliflozin as a result of
events of UTIs was rare and occurred in 0.2–0.3% of patients in
the dapagliflozin groups vs. 0.1% of patients in the placebo
group. Supplementary Table 2 includes details on baseline
characteristics, study duration and events of UTI in the
individual dapagliflozin studies [31,34–43].
8.1.2. Confirmed genital infections in the pooled analysis of
dapagliflozin clinical trials
As for UTIs, a rigorous effort was made to capture all signs,
symptoms and events suggestive of vulvovaginitis and balanitisby recording not only spontaneous reports of symptoms, but
also those reported during pro-active questioning of patients at
each visit throughout the dapagliflozin clinical program. The
pro-active questioning included itching, soreness or redness in
the genital area and a change or increase in genital discharge.
For safety signal detection, a broad range of preferred terms was
used to capture symptoms, signs and abnormal laboratory
findings suggestive of vulvovaginitis and balanitis, as well as
specific diagnoses. These preferred terms were described as
‘‘events suggestive of genital infections’’. In a second analysis,
35 pre-specified, preferred terms related to clinical diagnoses
were used to quantify diagnosed vulvovaginitis and balanitis,
and the diagnosis was made based on physical examination,
examination or culture of secretions, or by noting a therapeutic
response to treatment of fungal or other vaginal pathogens, but
physical examination for genital infections was not a protocol
requirement.
The events of clinical diagnoses indicative of genital
infections (not sexually transmitted diseases) were increased
with dapagliflozin 5 and 10 mg doses as compared with
placebo (with no clear dose relationship), and were more
frequent in women than men (Table 2) [44].
Patients with a history of recurrent genital yeast infections
were more likely to be diagnosed with genital infections
compared with those without a prior history, irrespective of
the treatment group (23.1% and 25% of patients in the
dapagliflozin 5 and 10 mg groups, respectively, and 10% in
the placebo group). Most first events of genital infections
occurred early in the course of treatment (mostly in the first 24
weeks), and recurrent infections were uncommon. Most
commonly reported events in women were vulvovaginal
mycotic infection, vaginal infection, and vulvovaginal can-
diasis. In men, balanitis, fungal genital infection, and balanitis
candida were most commonly reported.
The majority of patients responded to an initial standard
course of treatment. Inadequate response to an initial course
led to a need for an additional treatment in 6 (6.5%) and 3 (4.5%)
patients receiving dapagliflozin 5 and 10 mg groups, respec-
tively. Interruption or discontinuation of dapagliflozin as a
result of events of genital infections was rare, and occurred in
0–0.2% of patients in the dapagliflozin groups vs. 0% of patients
in the placebo group. Supplementary Table 2 includes details
on baseline characteristics, study duration and events of
genital infections in the individual dapagliflozin studies
[31,34–43].
Table 2 – Diagnosis of genital infections in dapagliflozin trials (up to 24 weeks).
Placebo Dapagliflozin 5 mg Dapagliflozin 10 mg
Overall number of patients, N 1393 1145 1193
Patients with diagnosis of genital infection, n (%) 12 (0.9) 65 (5.7) 57 (4.8)
Patients with history of recurrent genital infection, n (%) 10 (0.7) 13 (1.1) 12 (1.0)
Patients with a prior history of recurrent genital infection
with clinical diagnoses of genital infection, n (%)
1/10 (10) 3/13 (23.1) 3/12 (25.0)
Women
N 677 581 598
Women with diagnosed genital infection, n (%) 10 (1.5) 49 (8.4) 41 (6.9)
Men
N 716 564 595
Men with diagnosed genital infection, n (%) 2 (0.3) 16 (2.8) 16 (2.7)
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It is important to note that infections were not recorded using
a consistent methodology in the clinical trials of different
SGLT2 inhibitors, making it very difficult to compare infection
rates between different agents.
8.2.1. Canagliflozin
A phase 2 study of canagliflozin evaluated the prevalence of
bacteriuria and the frequency of AEs of UTIs in patients with
T2DM [45]. A mid-stream, clean-catch urine specimen was
used for dipstick analysis and culture at randomisation and at
week 12. In addition, self-administered vaginal swabs were
obtained at baseline and week 12, and at the time of a
vulvovaginal AE. These swabs were cultured for Candida
species. During the study, patients were asked open-ended
questions about AEs. An AE of a UTI was assessed by the
investigator. This included subjects with symptoms consis-
tent with UTIs, whether or not a urine culture was reported,
and also subjects with a positive urine culture identified,
irrespective of symptoms. The prevalence of bacteriuria, E. coli
bacteriuria, and candiduria was analysed for all patients with
available urine culture data either at baseline or at week 12,
and was stratified by gender. The initial prevalence of ASB was
6.4% and 6.5% in the pooled canagliflozin and placebo/
sitagliptin (control) groups, respectively, and was higher in
women. At week 12, no obvious differences in conversion from
negative baseline urine bacterial culture to positive culture
were observed in pooled canagliflozin vs. pooled sitagliptin/
placebo group (4.8% vs. 3.7%, respectively; p = 0.76); corre-
sponding with this, 14% and 25% of control and canagliflozin
patients with initial prevalent bacteriuria remained bacter-
iuric ( p = 0.65). The most common pathogens cultured were
E. coli and K. pneumoniae. UTIs (both symptomatic and positive
postbaseline urine culture reported as an AE) occurred in 21
(4.7%) patients: 16 (5.0%) in the pooled canagliflozin group and
5 (3.8%) in the pooled sitagliptin/placebo group (unadjusted
OR = 1.31; 95% CI: 0.45–4.68). The adjusted and non-adjusted
OR for UTIs with canagliflozin vs. sitagliptin/placebo were 2.39
(95% CI: 0.58–9.94) and 1.31 (95% CI: 0.45–4.68), respectively. All
UTIs were mild or moderate, and none led to study
discontinuation [45]. In conclusion, no differences in conver-
sion from negative baseline to positive urine bacterial cultures
and in the incidence of UTIs were observed in the pooled
canagliflozin and sitagliptin/placebo groups at 12 weeks.Further analysis of 215 women, from the phase 2 study
discussed above, was conducted to evaluate vaginal candida
colonization and symptomatic vulvovaginal AEs with canagli-
flozin treatment [46]. A clinical review of all AEs was
performed, prior to unblinding, to identify all vulvovaginal
AEs. All AEs were spontaneously reported and coded using the
MedDRA dictionary. To be included in this analysis, the AE had
to be symptomatic and either diagnosed by the investigator as
an infection or treated as an infection with a medication.
Vaginal swabs were collected from 198 women at baseline and
at week 12, and during the study in case symptoms of VVC
were noted. At baseline, 23/198 (12%) women had vaginal
cultures positive for Candida. Thirty one percent of canagli-
flozin and 14% of placebo/sitagliptin patients converted from
negative cultures at baseline to positive at week 12 (OR 2.8; 95%
CI of difference: 1.0–7.3). Vulvovaginal AEs were noted in 16
(10%) and 2 (3%) patients in the canagliflozin groups and
placebo/sitagliptin, respectively. Positive vaginal culture for
Candida species at baseline was found as a risk factor for
vulvovaginal AEs (OR 9.1; 95% CI: 2.4–34.0) [46]. Most of these
infections were treated with topical or oral antifungal
medications and resolved without study drug interruption.
Some of the recent canagliflozin studies have described the
incidence of UTIs and genital tract infections in patients with
T2DM over the longer-term. A large, randomised, double-
blind, active-controlled Phase III study compared canagliflozin
100 and 300 mg with glimepiride in patients with T2DM
(N = 1450) inadequately controlled with metformin. There
were modest elevations in UTIs in the canagliflozin groups (6%
each in the two canagliflozin groups) vs. comparator (5%) at 52
weeks. Higher rates of genital infections were noted in the
canagliflozin 100 and 300 mg groups (7% and 8% in men; 11%
and 14% in women) vs. comparator (1% in men and 2% in
women) at 52 weeks [47]. Another randomised, double-blind,
active-controlled, Phase 3 canagliflozin study in patients with
T2DM (N = 755) inadequately controlled with metformin plus a
sulfonylurea showed higher incidences of genital mycotic
infections in patients treated with canagliflozin 300 mg (9.2%
and 15.3% in men and women, respectively) vs. sitagliptin
100 mg (0.5% and 4.3% in men and women, respectively) at 52
weeks; however, these led to few study discontinuations.
Incidences of UTIs were similar in canagliflozin (4.0%) and
sitagliptin (5.6%) groups at 52 weeks [48].
In conclusion, more patients in the canagliflozin vs.
placebo/sitagliptin group converted from negative cultures
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there were modest elevations in UTIs and higher rates of
genital infections in the canagliflozin vs. sulphonylurea group.
Similar incidences of UTIs and higher incidences of genital
infections were noted in the canagliflozin vs. sitagliptin group
at 52 weeks. Supplementary Table 3 provides further informa-
tion on baseline characteristics, study duration and events of
genital infections and of UTI in the individual canagliflozin
studies.
8.2.2. Empagliflozin
A 12-week study in 408 treatment-naı¨ve patients with poorly
controlled T2DM reported UTIs in 1.2% of those receiving
empagliflozin, and 1.2% and 1.3% of those taking placebo and
metformin, respectively. Mycotic genital infections were
reported in 0.8% and genital pruritus in 1.2% of patients
receiving empagliflozin, and 0% for placebo and metformin
[49]. A 12-week study in 495 patients with T2DM inadequately
controlled with metformin found similar rates of UTIs in the
empagliflozin (4.0%) and sitagliptin (4.2%) groups; however,
slightly lower rates of UTIs were noted in the placebo group
(2.8%). AEs of genital infections were reported in the
empagliflozin (4.0%) and sitagliptin (2.8%) groups but not in
the placebo group [50]. Supplementary Table 4 provides
further information on baseline characteristics, study dura-
tion and events of genital infections and of UTI in the
individual empagliflozin studies.
8.2.3. Ipragliflozin
A phase 2 study in patients with T2DM randomised to
ipragliflozin or placebo reported UTIs in two female patients
at days 9 and 14 of a 28-day study. There were no reports of any
genital infections in the study [51]. Supplementary Table 4
provides further information on baseline characteristics,
study duration and events of genital infections and of UTI
in the ipragliflozin study.
9. Discussion and conclusions
Patients with T2DM are prone to UTIs and genital infections,
and various studies suggest that factors such as glucosuria
facilitating increased growth of bacteria, and increased
adherence of bacteria to the uroepithelium, might be linked
with the increased risk of these infections. However, the exact
mechanism by which patients with T2DM experience a greater
frequency of these infections is yet to be fully elucidated. This
widely recognized association, together with an increase in
urinary symptoms (particularly increased urinary volume and
bladder dysfunction) in patients with diabetes, may in itself
result in closer surveillance and hence, increased diagnosis of
infections. Persons without diabetes may be less likely to seek
medical advice for self-limiting infections, and the reported
prevalence may not be comparable with that of a population
with diabetes.
SGLT2 inhibitor-induced glucosuria likely plays a facilitat-
ing role in raising the risk of developing genital infections and,
to a lesser extent, UTIs. Upper UTIs (pyelonephritis) is not
increased with SGLT2 inhibitor treatment. The characteristics
of the infections associated with SGLT2 inhibition are similarto those in any population with diabetes, as these infections
respond to standard treatment and recur infrequently. In the
case of genital infections, increased infection rates appear to
be related to increased urinary glucose concentrations.
However, this association is less clear with UTIs, where
higher rates of infection were seen during treatment with the
5 mg dose of dapagliflozin vs. the 10 mg dose, despite lower
levels of urinary glucose excretion.
Despite the increasing body of data, there remains some
uncertainty around the true importance of UTIs and genital
infections associated with SGLT2 inhibitor therapy. Due to their
mechanism of action, SGLT2 inhibitors were expected to
increase glucosuria, a well-recognized risk factor for genital
infections. Because of this, infections have been closely
monitored during the clinical development of this class of
drugs. As a result, it is possible that events of UTIs were over-
reported in the SGLT2 clinical trials, with any tendency towards
over-reporting being similar in the placebo/control and inter-
vention groups. In addition, SGLT2 inhibitors are associated
with increased benign urinary symptoms (e.g. increased
urinary output) due to osmotic diuresis. This potentially may
have additionally increased the tendency towards diagnosis of
infection in patients treated with SGLT2 inhibitors.
To conclude, data from clinical trials of SGLT2 inhibitors
have shown that treatment of patients with T2DM is
accompanied by an increased risk of developing genital
infections and to a relatively lesser extent, UTIs. However, a
definitive dose relationship of the incidence of these infections
with the SGLT2 doses was not evident. Therefore, the precise
role of glucosuria as a causative factor for these infections
remains undetermined.
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